Short Interest in Elekta AB (OTCMKTS:EKTAY) Declines By 53.3%

Elekta AB (OTCMKTS:EKTAY) was the recipient of a large decrease in short interest in the month of April. As of April 30th, there was short interest totaling 669 shares, a decrease of 53.3% from the April 15th total of 1,433 shares. Based on an average trading volume of 1,312 shares, the short-interest ratio is currently 0.5 days. Currently, 0.0% of the shares of the company are sold short.

Elekta Stock Performance

Shares of OTCMKTS EKTAY traded down $0.22 during mid-day trading on Friday, hitting $5.83. The stock had a trading volume of 2,164 shares, compared to its average volume of 608. Elekta has a twelve month low of $4.35 and a twelve month high of $6.93. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.73 and a current ratio of 0.95. The firm has a market cap of $2.15 billion, a PE ratio of -582.02 and a beta of 1.01. The company has a 50 day moving average of $6.00 and a two-hundred day moving average of $5.90.

Elekta (OTCMKTS:EKTAY) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.09 earnings per share for the quarter. The company had revenue of $433.29 million for the quarter. Elekta had a positive return on equity of 12.84% and a negative net margin of 0.08%. Research analysts predict that Elekta will post 0.39 EPS for the current fiscal year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.